Targeting ischemic penumbra: part I - from pathophysiology to therapeutic strategy.
Targeting ischemic penumbra: part I - from pathophysiology to therapeutic strategy.
复制标题
DOI：
10.6030/1939-067x-3.1.47
复制
发表时间：
2010-03-15
期刊：
影响因子：
--
通讯作者：
Winn HR
中科院分区：
文献类型：
--
作者：
Liu S;Levine SR;Winn HR
半暗带是不可逆损伤的缺血核心周围的存活组织。急性中风治疗的目的是挽救半暗带组织和改善脑功能。然而，大多数具有可治疗的半暗带的急性中风患者不接受治疗。因此，开发一种有效的非再通疗法，如神经保护剂，具有重要的临床应用价值。第一部分，这一系列的审查“靶向半影”把特别强调半影病理生理学和治疗策略的发展。通过大规模代谢抑制和直接能量输送的生物能量干预将是一个有前途的未来方向。用于此目的的有效的药物递送系统应该能够穿透血脑屏障并实现高的局部组织药物水平，而非缺血区域在很大程度上不受影响。选择性给药至缺血性卒中半暗带是可行的，值得深入研究。
Penumbra is the viable tissue around the irreversibly damaged ischemic core. The purpose of acute stroke treatment is to salvage penumbral tissue and to improve brain function. However, the majority of acute stroke patients who have treatable penumbra are left untreated. Therefore, developing an effective non-recanalizational therapeutics, such as neuroprotective agents, has significant clinical applications. Part I of this serial review on “targeting penumbra” puts special emphases on penumbral pathophysiology and the development of therapeutic strategies. Bioenergetic intervention by massive metabolic suppression and direct energy delivery would be a promising future direction. An effective drug delivery system for this purpose should be able to penetrate BBB and achieve high local tissue drug levels while non-ischemic region being largely unaffected. Selective drug delivery to ischemic stroke penumbra is feasible and deserves intensive research.